AZD1152 in Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152
when given as a continuous 48-hour infusion every 14 days and as a 2-hour infusion for 2
consecutive days every 14 days in patients with advanced solid malignancies.